The total investment of the project is one hundred and eighty-eight million yuan (188 million yuan), of which: annual production capacity of 1,000 tons of aseptic raw material drug project investment of 100 million yuan, mainly the production of arginine (300 tons), alanyl glutamine (200 tons), invert sugar (200 tons), sodium ferulate (100 tons), anhydrous sodium carbonate (200 tons) and other aseptic raw material products, in October 2010, the construction started Construction began in October 2010, completed and put into operation in July 2011; export preparation processing base project investment of 88 million yuan, mainly the production of oral solid preparations (tablets, capsules, granules *** 10 billion tablets), 700 million water injections, 100 million powder injections. Plans to start construction in April 2011 to June 2012 completion and put into production.
The main construction content of the project: a comprehensive office building of 10,000 square meters, a power plant of 3,000 square meters, raw materials, export preparations, a warehouse of 12,000 square meters, aseptic raw materials workshop of four *** 10,000 square meters, export preparations production workshop of three *** 12,000 square meters, and other ancillary facilities of 2,000 square meters.
Three, environmental protection and energy saving
The production process of this project is mainly to re-refine and sterilize the raw materials, packaging and packaging process, the main auxiliary raw materials are purified water, a small amount of alcohol and activated charcoal, and the main power for the two 1,000 kVA transformers and a small amount of steam (supplied by Xingtai Ruijingkang Biotechnology Co., Ltd.). The pollution sources discharged by this project are a small amount of activated carbon (solid waste), living wastewater and cleaning and sanitation water (liquid waste is less than 50m³ per day), and low-decibel noise from the operation of machinery and equipment, which will not pollute the surrounding environment.
The project has carried out environmental evaluation and energy saving special evaluation, in line with the relevant national standards. The plant and its surroundings are greened according to the requirements of pharmaceutical production enterprises, which can not only beautify the environment, but also reduce environmental pollution.
Four, economic and social benefits
The completion of the project construction and put into operation, the annual output of 1,000 tons of sterile raw materials, oral solid preparations, 10 billion tablets, 700 million water needles and powder needles 100 million, with an annual sales income of more than 400 million yuan, profits and taxes of more than 80 million yuan, not only the economic benefits are considerable, but also can be exported to generate foreign exchange, but also for the local arrangements for more than 500 people to find employment.
Shijiazhuang Jingjing Pharmaceutical Co., Ltd.
Shijiazhuang Jingjing Pharmaceutical Co., Ltd. is a pharmaceutical company that produces and operates sterile APIs (arginine, anhydrous sodium carbonate) and other products.
The first to take the fastest action to convert the market demand into a real enterprise.
Enterprises producing cephalosporin-based products, the main excipients used as co-solvent sterile APIs - arginine, anhydrous sodium carbonate, etc. - must rely on imports, and the expensive price and the return of goods after quality problems are what they urgently need to solve. In view of this, Arginine was born.
The first to obtain legal approvals for sterile APIs - arginine and anhydrous sodium carbonate in China.
The first enterprise to realize the control of physical properties of finished products through the crystallization process.
The adjustment and control of the crystallization process stems from the fact that in order to meet the needs of different customers' production processes, and in the spirit of customers' convenience in operation, we reduce a processing link to ensure the quality of customers' final products.
The first company to produce clean clothes made of monofilament.
Visible foreign matter in injections can lead to adverse reactions such as phlebitis and vascular blockage in patients during use. One of the main factors leading to the excess of visible foreign matter is the shedding of cilia produced by the material of clean clothes, and monofilament clean clothes will effectively change this situation.
The company is located in Shijiazhuang City, Hebei Province, Gao Ying Street 17, covers an area of about 20,000 square meters, fixed assets of 8 million yuan, in full accordance with the requirements of sterile API GMP design, selection, installation, operation and management, and in December 2004 through the State Food and Drug Administration organization of the GMP certification.
The factory has a beautiful environment, with a reasonable layout of production area, auxiliary area and office area, and reasonable separation of human and logistic channels without mutual interference. There are 120 sets of main production equipments: air purification system, purified water system, water for injection system, dry heat sterilization cabinet, wet heat sterilization cabinet, crystal self-control crystallization tank, crystal filtering and drying equipment as well as quality analysis and inspection instruments, etc. All of them are first-class equipments in China.
The company now has more than 130 employees, including graduate students, college and university graduates and other technical personnel accounted for more than 50%, the main senior management personnel are senior engineers and licensed pharmacists with rich experience in pharmaceutical management. All the staff have been trained in GMP, professional knowledge and job operation skills. The company adheres to the people-oriented, scientific management, the establishment of a strict production management system and perfect quality assurance system, and in the entire production process to seriously implement, strict implementation, to ensure that the drug production management and quality control in practice.
The company's existing sterile APIs - arginine, anhydrous sodium carbonate for the country
Xingtai Ruijingkang Biotechnology Co.
Xingtai Ruijingkang Biotechnology Co., Ltd. is to produce and sell arginine and proline as the main products of amino acid series products of bio-manufacturing high-tech Ltd. is a high-tech enterprise in the biological manufacturing of amino acid series products. Located in Xingtai City, Hebei Province, Dacaozhuang management area; covers an area of 35.25 acres, *** there are 210 employees, now employing fourteen domestic well-known experts, 40 employees with college education, 90 employees with high school education, 4 senior titles. Since its establishment in 2007, the company has invested more than 30 million in fixed assets, and is expected to invest more than 50 million in fixed assets, which can produce 1,000 tons of proline or 650 tons of arginine annually. The company has a beautiful environment and is a joint-stock bioengineering high-tech enterprise with flourishing development.
Xingtai Ruijingkang Bio-technology Co., Ltd. has developed two varieties of arginine and proline successfully. The newly-built production line adopts the best air compressor, freezer and automatic control device in China for fermentation; the extraction adopts advanced concentration equipment and imported membrane equipment in China, and the product quality reaches the standard of pharmaceutical grade.
Arginine fermentation varieties of national fifteen key research to fill the gaps in the project, in the field of medicine, nutrition, health care, food and other areas of wide application, high demand, called the medicinal amino acid is one of the most important varieties. Pilot acid production 7.5%, extraction yield reached 65%. After the Hebei Provincial Science and Technology Department Achievement Appraisal Center appraisal as "domestic leading, international advanced level". The new production line can produce 650 tons of arginine per year, realizing output value of 58.5 million yuan/year, profit of 29.25 million yuan/year, net profit of 23.4 million yuan/year, and tax of 5.85 million yuan/year. The produced arginine products are mainly supplied to Shijiazhuang Jingjing Pharmaceuticals for use and production of ornithine, citrulline and other high value-added products.
Proline has been successfully tested and is the second enterprise with industrialized production capacity in China. Mainly used in I.V. and synthesized captopril, enalapril and other antihypertensive drugs, has been widely used in the food and pharmaceutical industry easy to mix with a variety of feed, premixes, multi-dimensional homogeneous, can be directly in the feed or additives production of general-purpose equipment. Widely used as vitamin C additives in feed, is used in a variety of feed and multi-dimensional production needs, especially for fish pellet feed processing, improve the efficiency of the aquaculture industry. It is also an important raw material for amino acid infusion, and the market application prospect is very broad. It is one of the newly developed new varieties of high value-added amino acids in recent years. The level of acid production reached 7% in the pilot test, and the only domestic production is made by Guangdong Star Lake Technology Co. The sales will first utilize the sales network already formed by the shareholders of the company, and then develop the company's own sales network. The company's new production line can produce 1,000 tons of proline per year. The company is in the process of self-export business, and will realize self-export at that time. It can realize gross profit of 66 million yuan/year, net profit of 52.8 million yuan/year, and pay taxes of 10.56 million yuan/year.
Xingtai Ruijingkang Biotechnology Co., Ltd. adheres to the development strategy of relying on technology for development and technological innovation, and vigorously develops cooperation with various colleges and universities, research institutes and large domestic pharmaceutical factories. We have cooperated with Shanghai Institute of Engineering and Microbiology to develop amino acid series products, and completed the laboratory test of tryptophan. We plan to develop other high value-added amino acid varieties such as serine, cystine and other high value-added products. We have continued to cooperate with Shenyang Branch of Chinese Academy of Sciences to successfully develop high protein short peptide feed for aquaculture. Continued cooperation with the Tianjin Institute of Light Industry to improve the boiler flue gas desulphurization and sewage treatment linkage technology, adding a new highlight for the country's environmental protection industry, will become a new profit growth point for the company. The company vigorously develops talent strategy, and establishes talent training mechanism with universities and colleges to provide high-quality technical personnel for the company's future development.
The second phase of the amino acid fermentation workshop, which is under demonstration, is planned to invest 150-200 million yuan in five years to build a production line with an annual output of 4,000 tons of proline, which can realize an annual output value of 504 million yuan, an annual profit of 264 million yuan, and taxes of 52.8 million yuan, and ultimately realize the listing of the company's financing and complete the qualitative leap. The company has more than 700 employees, the company's shareholders and all employees are confident that the enterprise will develop into a star enterprise in the biological manufacturing industry.